LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Heditsian, Diane"
  2. AU="Almane, Dace N"
  3. AU="Lerman, Dorothea C."
  4. AU="Góes, C"
  5. AU="Searle, Philip A"
  6. AU="Hudecek, Michael"
  7. AU="Joyce, Doireann P."
  8. AU="Müller, Werner Eg"
  9. AU="Takahashi, Tsutomo"
  10. AU="Jenny Zhaoying Xiang"
  11. AU=Ferraro Elisabetta
  12. AU="Jonathan Downar"
  13. AU=Rahmanzade Ramin AU=Rahmanzade Ramin
  14. AU="Edwards, Lisa-Jayne"
  15. AU="Tominaga, Shintaro"
  16. AU="Chan, Brian"
  17. AU="Julieta Carilla"

Suchergebnis

Treffer 1 - 6 von insgesamt 6

Suchoptionen

  1. Artikel ; Online: 18

    Diwanji, Devan / Onishi, Natsuko / Hathi, Deep K / Lawhn-Heath, Courtney / Kornak, John / Li, Wen / Guo, Ruby / Molina-Vega, Julissa / Seo, Youngho / Flavell, Robert R / Heditsian, Diane / Brain, Susie / Esserman, Laura J / Joe, Bonnie N / Hylton, Nola M / Jones, Ella F / Ray, Kimberly M

    Radiology. Imaging cancer

    2024  Band 6, Heft 2, Seite(n) e230082

    Abstract: Purpose To compare quantitative measures of tumor metabolism and perfusion using fluorine 18 ( ...

    Abstract Purpose To compare quantitative measures of tumor metabolism and perfusion using fluorine 18 (
    Mesh-Begriff(e) Humans ; Female ; Fluorodeoxyglucose F18/therapeutic use ; Neoadjuvant Therapy ; Ki-67 Antigen ; Positron-Emission Tomography/methods ; Breast Neoplasms/diagnostic imaging ; Breast Neoplasms/drug therapy ; Breast Neoplasms/metabolism ; Magnetic Resonance Imaging
    Chemische Substanzen Fluorodeoxyglucose F18 (0Z5B2CJX4D) ; Ki-67 Antigen
    Sprache Englisch
    Erscheinungsdatum 2024-03-29
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ISSN 2638-616X
    ISSN (online) 2638-616X
    DOI 10.1148/rycan.230082
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  2. Artikel ; Online: Patient perspectives on window of opportunity clinical trials in early-stage breast cancer.

    Parikh, Divya A / Kody, Lisa / Brain, Susie / Heditsian, Diane / Lee, Vivian / Curtis, Christina / Karin, Mardi R / Wapnir, Irene L / Patel, Manali I / Sledge, George W / Caswell-Jin, Jennifer L

    Breast cancer research and treatment

    2022  Band 194, Heft 1, Seite(n) 171–178

    Abstract: Purpose: Window of opportunity trials (WOT) are increasingly common in oncology research. In WOT participants receive a drug between diagnosis and anti-cancer treatment, usually for the purpose of investigating that drugs effect on cancer biology. This ... ...

    Abstract Purpose: Window of opportunity trials (WOT) are increasingly common in oncology research. In WOT participants receive a drug between diagnosis and anti-cancer treatment, usually for the purpose of investigating that drugs effect on cancer biology. This qualitative study aimed to understand patient perspectives on WOT.
    Methods: We recruited adults diagnosed with early-stage breast cancer awaiting definitive therapy at a single-academic medical center to participate in semi-structured interviews. Thematic and content analyses were performed to identify attitudes and factors that would influence decisions about WOT participation.
    Results: We interviewed 25 women diagnosed with early-stage breast cancer. The most common positive attitudes toward trial participation were a desire to contribute to research and a hope for personal benefit, while the most common concerns were the potential for side effects and how they might impact fitness for planned treatment. Participants indicated family would be an important normative factor in decision-making and, during the COVID-19 pandemic, deemed the absence of family members during clinic visits a barrier to enrollment. Factors that could hinder participation included delay in standard treatment and the requirement for additional visits or procedures. Ultimately, most interviewees stated they would participate in a WOT if offered (N = 17/25).
    Conclusion: In this qualitative study, interviewees weighed altruism and hypothetical personal benefit against the possibility of side effect from a WOT. In-person family presence during trial discussion, challenging during COVID-19, was important for many. Our results may inform trial design and communication approaches in future window of opportunity efforts.
    Mesh-Begriff(e) Adult ; Breast Neoplasms/drug therapy ; Breast Neoplasms/therapy ; COVID-19 ; Clinical Trials as Topic ; Communication ; Female ; Humans ; Pandemics ; Qualitative Research
    Sprache Englisch
    Erscheinungsdatum 2022-05-11
    Erscheinungsland Netherlands
    Dokumenttyp Journal Article
    ZDB-ID 604563-7
    ISSN 1573-7217 ; 0167-6806
    ISSN (online) 1573-7217
    ISSN 0167-6806
    DOI 10.1007/s10549-022-06611-6
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1655: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Rationale, Study Design, and Cohort Characteristics for the Markers for Environmental Exposures (MEE) Study.

    Lucia, Rachel McFarland / Huang, Wei-Lin / Alvarez, Andrea / Thampy, Daphne / Elyasian, Melodie / Hidajat, Amanda / Yang, Kailynn / Forman, Danielle / Pebdani, Asana / Masunaka, Irene / Brain, Susie / Heditsian, Diane / Lee, Vivian / Goodman, Deborah / Norden-Krichmar, Trina M / Odegaard, Andrew O / Ziogas, Argyrios / Park, Hannah Lui

    International journal of environmental research and public health

    2020  Band 17, Heft 5

    Abstract: Environmental factors have been linked to many diseases and health conditions, but reliable assessment of environmental exposures is challenging. Developing biomarkers of environmental exposures, rather than relying on self-report, will improve our ... ...

    Abstract Environmental factors have been linked to many diseases and health conditions, but reliable assessment of environmental exposures is challenging. Developing biomarkers of environmental exposures, rather than relying on self-report, will improve our ability to assess the association of such exposures with disease. Epigenetic markers, most notably DNA methylation, have been identified for some environmental exposures, but identification of markers for additional exposures is still needed. The rationale behind the Markers for Environmental Exposures (MEE) Study was to (1) identify biomarkers, especially epigenetic markers, of environmental exposures, such as pesticides, air/food/water contaminants, and industrial chemicals that are commonly encountered in the general population; and (2) support the study of potential relationships between environmental exposures and health and health-related factors. The MEE Study is a cross-sectional study with potential for record linkage and follow-up. The well-characterized cohort of 400 postmenopausal women has generated a repository of biospecimens, including blood, urine, and saliva samples. Paired data include an environmental exposures questionnaire, a breast health questionnaire, dietary recalls, and a food frequency questionnaire. This work describes the rationale, study design, and cohort characteristics of the MEE Study. In addition to our primary research goals, we hope that the data and biorepository generated by this study will serve as a resource for future studies and collaboration.
    Mesh-Begriff(e) Biomarkers ; Cohort Studies ; Cross-Sectional Studies ; Environmental Exposure ; Female ; Humans ; Pesticides
    Chemische Substanzen Biomarkers ; Pesticides
    Sprache Englisch
    Erscheinungsdatum 2020-03-09
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 1660-4601
    ISSN (online) 1660-4601
    DOI 10.3390/ijerph17051774
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  4. Artikel ; Online: The WISDOM study: a new approach to screening can and should be tested.

    Esserman, Laura / Eklund, Martin / Veer, Laura Van't / Shieh, Yiwey / Tice, Jeffrey / Ziv, Elad / Blanco, Amie / Kaplan, Celia / Hiatt, Robert / Fiscalini, Allison Stover / Yau, Christina / Scheuner, Maren / Naeim, Arash / Wenger, Neil / Lee, Vivian / Heditsian, Diane / Brain, Susie / Parker, Barbara A / LaCroix, Andrea Z /
    Madlensky, Lisa / Hogarth, Michael / Borowsky, Alexander / Anton-Culver, Hoda / Kaster, Andrea / Olopade, Olufunmilayo I / Sheth, Deepa / Garcia, Augustin / Lancaster, Rachael / Plaza, Michael

    Breast cancer research and treatment

    2021  Band 189, Heft 3, Seite(n) 593–598

    Mesh-Begriff(e) Breast Neoplasms ; Female ; Humans ; Mass Screening ; Research
    Sprache Englisch
    Erscheinungsdatum 2021-09-16
    Erscheinungsland Netherlands
    Dokumenttyp Editorial
    ZDB-ID 604563-7
    ISSN 1573-7217 ; 0167-6806
    ISSN (online) 1573-7217
    ISSN 0167-6806
    DOI 10.1007/s10549-021-06346-w
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1655: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  5. Artikel ; Online: Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.

    Bartelink, Imke H / Prideaux, Brendan / Krings, Gregor / Wilmes, Lisa / Lee, Pei Rong Evelyn / Bo, Pan / Hann, Byron / Coppé, Jean-Philippe / Heditsian, Diane / Swigart-Brown, Lamorna / Jones, Ella F / Magnitsky, Sergey / Keizer, Ron J / de Vries, Niels / Rosing, Hilde / Pawlowska, Nela / Thomas, Scott / Dhawan, Mallika / Aggarwal, Rahul /
    Munster, Pamela N / Esserman, Laura J / Ruan, Weiming / Wu, Alan H B / Yee, Douglas / Dartois, Véronique / Savic, Radojka M / Wolf, Denise M / van 't Veer, Laura

    Breast cancer research : BCR

    2017  Band 19, Heft 1, Seite(n) 107

    Abstract: Background: Poly(ADP-ribose) polymerase inhibitors (PARPi), coupled to a DNA damaging agent is a promising approach to treating triple negative breast cancer (TNBC). However, not all patients respond; we hypothesize that non-response in some patients ... ...

    Abstract Background: Poly(ADP-ribose) polymerase inhibitors (PARPi), coupled to a DNA damaging agent is a promising approach to treating triple negative breast cancer (TNBC). However, not all patients respond; we hypothesize that non-response in some patients may be due to insufficient drug penetration. As a first step to testing this hypothesis, we quantified and visualized veliparib and carboplatin penetration in mouse xenograft TNBCs and patient blood samples.
    Methods: MDA-MB-231, HCC70 or MDA-MB-436 human TNBC cells were implanted in 41 beige SCID mice. Low dose (20 mg/kg) or high dose (60 mg/kg) veliparib was given three times daily for three days, with carboplatin (60 mg/kg) administered twice. In addition, blood samples were analyzed from 19 patients from a phase 1 study of carboplatin + PARPi talazoparib. Veliparib and carboplatin was quantified using liquid chromatography-mass spectrometry (LC-MS). Veliparib tissue penetration was visualized using matrix-assisted laser desorption/ionization mass spectrometric imaging (MALDI-MSI) and platinum adducts (covalent nuclear DNA-binding) were quantified using inductively coupled plasma-mass spectrometry (ICP-MS). Pharmacokinetic modeling and Pearson's correlation were used to explore associations between concentrations in plasma, tumor cells and peripheral blood mononuclear cells (PBMCs).
    Results: Veliparib penetration in xenograft tumors was highly heterogeneous between and within tumors. Only 35% (CI 95% 26-44%), 74% (40-97%) and 46% (9-37%) of veliparib observed in plasma penetrated into MDA-MB-231, HCC70 and MDA-MB-436 cell-based xenografts, respectively. Within tumors, penetration heterogeneity was larger with the 60 mg/kg compared to the 20 mg/kg dose (RSD 155% versus 255%, P = 0.001). These tumor concentrations were predicted similar to clinical dosing levels, but predicted tumor concentrations were below half maximal concentration values as threshold of response. Xenograft veliparib concentrations correlated positively with platinum adduct formation (R
    Conclusions: PARPi/platinum tumor penetration can be measured by MALDI-MSI and ICP-MS in PBMCs and fresh frozen, OCT embedded core needle biopsies. Large variability in platinum adduct formation and spatial heterogeneity in veliparib distribution may lead to insufficient drug exposure in select cell populations.
    Mesh-Begriff(e) Animals ; Benzimidazoles/administration & dosage ; Benzimidazoles/chemistry ; Carboplatin/administration & dosage ; Carboplatin/chemistry ; Cell Line, Tumor ; Female ; Humans ; Leukocytes, Mononuclear/drug effects ; Mice ; Penetrance ; Poly(ADP-ribose) Polymerase Inhibitors/administration & dosage ; Poly(ADP-ribose) Polymerase Inhibitors/chemistry ; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization ; Triple Negative Breast Neoplasms/drug therapy ; Triple Negative Breast Neoplasms/pathology ; Xenograft Model Antitumor Assays
    Chemische Substanzen Benzimidazoles ; Poly(ADP-ribose) Polymerase Inhibitors ; veliparib (01O4K0631N) ; Carboplatin (BG3F62OND5)
    Sprache Englisch
    Erscheinungsdatum 2017-09-11
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 2015059-3
    ISSN 1465-542X ; 1465-5411
    ISSN (online) 1465-542X
    ISSN 1465-5411
    DOI 10.1186/s13058-017-0896-4
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 5494: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  6. Artikel ; Online: Advocates' perspective: neoadjuvant chemotherapy for breast cancer.

    Perlmutter, Jane / Axler, Susan / Baas, Carole / Beckwith, Barbara J / Bonoff, Amy / Brain, Susan / Delapine, Maryellen / Devine, Margaret / Frank, Elizabeth / Fraser, Valerie / Gallece, Marjorie / Geoghegan, Cindy / Hamade, Hiam / Heditsian, Diane / Hirschhorn, Bonnie / Kandell, Stephen / Laxague, Deborah / Lestage, Barbara / Lyzen, Maria /
    Madden, Debra / Mertz, Shirley A / Parker, Beverly J / Roach, Nancy / Sauers, Nancy / Vincent, Linda / Waddell, Dorothy / Wetzel, Maria / Wright, Kimberly

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2012  Band 30, Heft 36, Seite(n) 4586–8; author reply 4588–9

    Mesh-Begriff(e) Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Breast Neoplasms/therapy ; Carcinoma in Situ/therapy ; Carcinoma, Ductal, Breast/therapy ; Female ; Humans ; Mastectomy ; Neoadjuvant Therapy
    Sprache Englisch
    Erscheinungsdatum 2012-12-20
    Erscheinungsland United States
    Dokumenttyp Comment ; Letter
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.2012.44.1824
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1847: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 650: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang